Search Result

Results for "

Sp-8-Br-2'-O-Me-cAMPS

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Acyltransferase (1) Adenosine Receptor (8) Adenylate Cyclase (1) Amyloid-β (1) Apelin Receptor (APJ) (3) Apoptosis (4) Arrestin (3) Biochemical Assay Reagents (1) Calmodulin (1) Cannabinoid Receptor (2) CFTR (1) CGRP Receptor (1) Cholinesterase (ChE) (1) Dopamine Receptor (3) Endogenous Metabolite (2) Fluorescent Dye (3) G protein-coupled Bile Acid Receptor 1 (1) GCGR (2) GPR84 (1) Mas-related G-protein-coupled Receptor (MRGPR) (1) Melanocortin Receptor (1) Neprilysin (1) Neuromedin U Receptor (NMUR) (1) Neuropeptide Y Receptor (1) Opioid Receptor (1) Phosphodiesterase (PDE) (16) PKA (34) PKC (2) Potassium Channel (1) Prostaglandin Receptor (2) Ras (9) Reactive Oxygen Species (ROS) (2) Reference Standards (3) Small Interfering RNA (siRNA) (1) Somatostatin Receptor (1) Succinate Receptor 1 (1) TSH Receptor (1)
By Research Areas:	Cancer (14) Cardiovascular Disease (12) Endocrinology (3) Inflammation/Immunology (20) Metabolic Disease (19) Neurological Disease (33)
Click Chemistry:	Azide (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) siRNAs (1)

100

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0764

Bucladesine sodium Maximum Cited Publications 43 Publications Verification Dibutyryl cAMP sodium; DBcAMP sodium	PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-100927

Ro 20-1724 Ro 20-174	Phosphodiesterase (PDE)	Neurological Disease
Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase (PDE4/PDE IV) with a K_i of 1930 nM. Neuroprotective effect .

HY-100530D

*Rp-cAMPS* sodium salt** 5 Publications Verification	PKA	Neurological Disease
Rp-cAMPS sodium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS sodium salt is resistant to hydrolysis by phosphodiesterases .

HY-P3366

Ecnoglutide XW003	GCGR	Metabolic Disease
Ecnoglutide (XW003) is a long-acting, cAMP-biased glucagon-like peptide 1 (GLP-1) receptor agonist. Ecnoglutide can be used for research of T2DM and obesity .

HY-117656

ESI-05 4 Publications Verification NSC 116966	Acyltransferase	Neurological Disease Metabolic Disease
ESI-05 is a specific *exchange proteins directly activated by cAMP* 2 (EPAC2)** inhibitor. ESI-05 inhibits cAMP-mediated EPAC2 GEF activity with an IC₅₀ of 0.43 μM. ESI-05 can be used for the research of diabetes, insulin secretion and neurological disorders .

HY-125791

cis-Epoxysuccinic acid 3 Publications Verification	Succinate Receptor 1	Cardiovascular Disease
cis-Epoxysuccinic acid is a succinate receptor (SUCNR1/GPR91) agonist. cis-Epoxysuccinic acid inhibits cAMP levels with an EC₅₀ value of 2.7 μM. cis-Epoxysuccinic acid can be used for the research of cardiovascular system .

HY-124151

Adenosine-2'-monophosphate 2'-AMP; Adenosine 2'-phosphate; AMP 2'-phosphate	Adenosine Receptor Endogenous Metabolite	Neurological Disease
Adenosine-2'-monophosphate (2'-AMP) is converted by extracellular 2’,3'-CAMP. Adenosine-2'-monophosphate is further metabolized to extracellular adenosine (a mechanism called the extracellular 2’,3’-cAMP-adenosine pathway). Adenosine-2'-monophosphate inhibits LPS-induced TNF-α and CXCL10 production via A_2A receptor activation .

HY-136172

ESI-08 1 Publications Verification	Ras	Cardiovascular Disease Metabolic Disease Cancer
ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC₅₀ of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation .

HY-B0392

(S)-(+)-Rolipram (+)-Rolipram; (S)-Rolipram	Phosphodiesterase (PDE) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
(S)-(+)-Rolipram ((+)-Rolipram) is a cyclic AMP(cAMP)-specific phosphodiesterase 4 (PDE4) inhibitor, with an IC₅₀ of 1100 nM. (S)-(+)-Rolipram can suppresse tumor necrosis factor-alpha (TNFα) production by human mononuclear cells .

HY-100530C

*Sp-cAMPS* sodium salt**	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS sodium salt, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS sodium salt is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS sodium salt binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-103180

2'-MeCCPA 2-Chloro-N-cyclopentyl-2′-C-methyladenosine	Adenosine Receptor	Neurological Disease
2'-MeCCPA is a potent and selective A1 adenosine receptors (A1AR) agonist. 2'-MeCCPA efficiently inhibits cAMP modulation in both direct pathway medium spiny neurons (dMSNs) and indirect pathway medium spiny neurons (iMSNs) .

HY-P2197

ELA-11(human)	Apelin Receptor (APJ) Arrestin	Inflammation/Immunology
ELA-11(human), a peptide, is a full agonist of human apelin receptor, with a pK_i of 7.85. ELA-11(human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment .

HY-137640A

*Sp-8-Br-cAMPS* sodium**	PKA	Inflammation/Immunology
Sp-8-Br-cAMPS sodium is a cAMP analog, which performs a protein kinase A (PKA) activating activity with EC₅₀ of 360 nM. Sp-8-Br-cAMPS sodium inhibits proliferation of T cells and the haemocyte non-self response in Lepidoptera larve .

HY-P2249

ELA-21 (human)	Arrestin Apelin Receptor (APJ)	Cardiovascular Disease
ELA-21 (human) is an apelin receptor agonist with a pK_i of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways .

HY-134266

8-Bromo-AMP 1 Publications Verification 8-Bromoadenosine 5'-monophosphate; 8-Bromoadenylic acid	Endogenous Metabolite	Cardiovascular Disease
8-Bromo-AMP (8-Bromoadenosine 5'-monophosphate) is a membrane permeable cAMP analogue. 8-Bromo-AMP can improve the ability of the heart to recover from ischemia and reperfusion by increasing the levels of ATP, ADP, and total adenine nucleotides .

HY-50158

Glucagon receptor antagonist-2	GCGR	Metabolic Disease Inflammation/Immunology
Glucagon receptor antagonist-2 is a glucagon receptor antagonist. Glucagon receptor antagonist-2 functionally inhibits receptor activity via reduced cAMP production. Glucagon receptor antagonist-2 can be used for the research of type 2 diabetes .

HY-153213A

Org 274178-0	TSH Receptor	Endocrinology
Org 274178-0 is a selective thyroid-stimulating hormone receptor (TSHR) antagonist with a pIC₅₀ value for TSHR is 5.03. Org 274178-0 inhibits the activation of cAMP signaling pathway and phospholipase C (PLC) signaling pathway mediated by thyroid-stimulating hormone (TSH) and TSH receptor-stimulating immunoglobulins (TSIs). Org 274178-0 is promising for research of Graves’ disease and Graves’ ophthalmopathy .

HY-100530A

Rp-cAMPS	PKA	Neurological Disease
Rp-cAMPS, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS is resistant to hydrolysis by phosphodiesterases .

HY-100530

*Rp-cAMPS* triethylammonium salt** 5 Publications Verification	PKA	Neurological Disease
Rp-cAMPS triethylammonium salt, a cAMP analog, is a potent, competitive cAMP-induced activation of cAMP-dependent PKA I and II (K_is of 12.5 µM and 4.5 µM, respectively) antagonist. Rp-cAMPS triethylammonium salt is resistant to hydrolysis by phosphodiesterases .

HY-137640C

*Rp-8-Br-cAMPS* sodium** 1 Publications Verification	PKA	Inflammation/Immunology Cancer
Rp-8-Br-cAMPS sodium is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS sodium occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS sodium can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS sodium also inhibits insulin secretion .

HY-120994B

Sp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Sp-8-CPT-cAMPS, a cAMP analog, is a potent and selective activator of the cAMP-dependent protein kinas A (PKA I and PKA II). Sp-8-CPT-cAMPS selects site A of RI compares to site A of RII by 153-fold and site B of RII compares to site B of RI by 59-fold .

HY-131768

2'-O-Succinyl-cAMP	Cholinesterase (ChE)	Others
2'-O-Succinyl-cAMP is a cAMP analog that can be covalently coupled to acetylcholinesterase. 2'-O-Succinyl-cAMP conjugate has been used as tracers in a classical heterogeneous competitive enzyme immunoassay allowing the determination of cAMP .

HY-134254

8-AHA-cAMP 8-(6-Aminohexylamino)-cAMP	Biochemical Assay Reagents	Others
8-AHA-cAMP (8-(6-Aminohexylamino)-cAMP) is a cAMP derivative that modulates the function of proteins by interacting with their cAMP binding domain (CNBD). 8-AHA-cAMP can be used to reveal the mechanism of action of cAMP in cell signaling .

HY-P1325

BWX 46 ((Cys31, Nva 34)-Neuropeptide Y (27-36))2	Neuropeptide Y Receptor	Neurological Disease
BWX 46 (((Cys31, Nva 34)-Neuropeptide Y (27-36))2) is a selective Y₅ receptor agonist with an IC₅₀ value of 0.85 nM. BWX 46 can inhibit the synthesis of cAMP in Y₅ cells .

HY-B0764R

Bucladesine sodium (Standard) Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)	Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .

HY-131032

KI-7	Adenosine Receptor	Others
KI-7 is an A2B adenosine receptor positive allosteric modulator. KI-7 potentiates the cAMP accumulation induced by the non-selective A2B adenosine receptor agonist NECA (EC₅₀=445.8 nM). KI-7 also potentiates the cAMP accumulation induced by the selective A2B adenosine receptor agonist BAY 60-6583 as well as by adenosine with EC₅₀s of 2390 nM and 2550 nM, respectively .

HY-149933

AM841	Cannabinoid Receptor	Neurological Disease
AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility .

HY-100530B

Sp-cAMPS	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-110005

*Sp-cAMPS* triethylamine**	PKA Phosphodiesterase (PDE)	Neurological Disease Metabolic Disease
Sp-cAMPS triethylamine, a cAMP analog, is potent activator of cAMP-dependent PKA I and PKA II. Sp-cAMPS triethylamine is also a potent, competitive phosphodiesterase (PDE3A) inhibitor with a K_i of 47.6 µM. Sp-cAMPS triethylamine binds the PDE10 GAF domain with an EC₅₀ of 40 μM .

HY-P3786

H-Arg-Gly-Tyr-Ala-Leu-Gly-OH	PKA PKC	Cancer
H-Arg-Gly-Tyr-Ala-Leu-Gly-OH is a competitive and CAMP dependent protein kinase inhibitor .

HY-P3770

Phosphate acceptor peptide	PKC	Others
Phosphate acceptor peptide is a substrate for cAMP-dependent protein kinase (PKA). phosphate acceptor peptide is also a weak PKC inhibitor .

HY-W349178

Medorinone	Phosphodiesterase (PDE)	Cardiovascular Disease
Medorinone is an inhibitor of cAMP phosphodiesterase activity. Medorinone can be used as a cardiac stimulant/vasodilator .

HY-106303

YT 146	Adenosine Receptor	Cardiovascular Disease
YT 146 is a potent agonist of A2 adenosine receptor (A2 AR) agonist. YT 146 causes a concentreation dependent cAMP accumulation, with the EC₅₀ of 1.5 nM. YT 146 has cardioprotective effects .

HY-141495

(Rac)-Razpipadon 1 Publications Verification PW0464	Dopamine Receptor	Neurological Disease
PW0464, a nanomolar potent complete G protein biased ligand, is a noncatechol D1R agonist, with an EC₅₀ of 5.8 nM (Gs-cAMP) .

HY-178982

Apelin agonist 2	Apelin Receptor (APJ)	Metabolic Disease
Apelin agonist 2 (Compound 35) is an orally active APLNR agonist. Apelin agonist 2 can significantly inhibit the accumulation of cAMP (EC₅₀ = 10 nM). Apelin agonist 2 exhibits a significant improvement in glucose tolerance. Apelin agonist 2 can be used to study metabolic diseases such as diabetes .

HY-P0252B

α-MSH free acid α-Melanocyte-Stimulating Hormone free acid	Melanocortin Receptor	Neurological Disease
α-MSH free acid (α-Melanocyte-Stimulating Hormone free acid) is an MC3R and MC4R agonist with EC₅₀s of 0.16 nM and 5.6 nM, respectively. α-MSH free acid activates cAMP generation at MC3R and MC4R .

HY-120994A

Rp-8-CPT-cAMPS	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-137640B

Rp-8-Br-cAMPS	PKA	Inflammation/Immunology Cancer
Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion .

HY-134263

*8-Br-cAMP-AM*	PKA Ras	Cardiovascular Disease
8-Br-cAMP-AM is a cyclic adenosine monophosphate (cAMP) analog that activates two major signal transduction pathways in the heart by mimicking the effects of cAMP: protein kinase A (PKA) and guanosine nucleotide exchange factor (Epac), which is directly activated by cAMP. 8-Br-cAMP-AM can be used to study cardiac ischemia and reperfusion injury .

HY-N3550

Catalponol	Others	Cancer
Catalponol is a naphthoquinone derivative. Catalponol enhances dopamine biosynthesis by inducing tyrosine hydroxylase activity. Catalponol also increases the levels of cAMP and tyrosine hydroxylase phosphorylation in PC12 cells .

HY-130786

Denbufylline BRL 30892	Phosphodiesterase (PDE)	Others Inflammation/Immunology
Denbufylline (BRL 30892) is an inhibitor of phosphodiesterase-4 (PDE4). Denbufylline is able to block the degradation of intracellular cAMP (cyclic adenosine phosphate) thereby increasing the level of intracellular cAMP, which helps regulate a variety of cellular functions. Denbufylline can be used in the study of chronic obstructive pulmonary disease (COPD), asthma and other inflammatory diseases .

HY-137370

2-Hexynyl-5′-N-ethylcarboxamidoadenosine HENECA; 2-Hexynyl-NECA	Adenosine Receptor Amyloid-β	Neurological Disease
2-Hexynyl-5′-N-ethylcarboxamidoadenosine (HENECA) is a selective A_2A adenosine receptor agonist. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine increases intracellular cAMP level, and inhibits TNFα-evoked MMP-3 release. 2-Hexynyl-5′-N-ethylcarboxamidoadenosine induces Aβ42 production in SH-SY5Y cells .

HY-N2658

5,7-Diacetoxy-8-methoxyflavone	Phosphodiesterase (PDE)	Others
5,7-Diacetoxy-8-methoxyflavone is a natural product that could come from scutellaria genus plants. 5,7-Diacetoxy-8-methoxyflavone has inhibitory activity for cAMP phosphodiesterase .

HY-161107

OX04529	GPR84	Inflammation/Immunology
OX04529 (compound 69) is a potent, selective and orally active agonist of GPR84. OX04529 inhibits FSK-induced cAMP production with an EC₅₀ of 0.0185 nM. OX04529 displayed excellent potency, high G-protein signaling bias .

HY-14326

L-750667	Dopamine Receptor	Neurological Disease
L-750667 is a selective dopamine D4 receptor antagonist ligand. ¹²⁵I-labeled L-750667 can specifically bind to dopamine D4 receptors in the rat retina, with a K_d value of 0.06 nM. L-750667 is involved in the regulation of the light-sensitive cAMP pool .

HY-117064

NY-0173	Ras	Others
NY-0173 is an antagonist of Exchange proteins directly activated by cAMP (EPAC), with IC₅₀s of 3.5 μM (EPAC2)and 4.0 μM (EPAC1) respectively. NY-0173 can be used to elucidate the biological functions of EPAC .

HY-124681

NY0116	Neuromedin U Receptor (NMUR)	Metabolic Disease
NY0116 is a neuromedin U receptor 2 (NMUR2) agonist with EC₅₀ values of 27.76 μM for hNMUR1 and 13.61 μM for hNMUR2. NY0116 decreases cAMP while stimulating calcium signaling in stably expressing NMUR2 HEK293 cells .

HY-177493A

SSTR3 agonist-1 TFA	Somatostatin Receptor	Metabolic Disease Endocrinology
SSTR3 agonist-1 TFA is a potent, orally active, and selective SSTR3 agnoist (EC₅₀ =0.14 nM). SSTR3 agonist-1 TFA binds to SSTR3 receptor to inhibit cAMP activity. SSTR3 agonist-1 TFA decreases kidney weight and kidney cystic index (KCI) in a mouse model of autosomal dominant polycystic kidney disease (ADPKD). SSTR3 agonist-1 TFA can be used for ADPKD research .

HY-120994

*Rp-8-CPT-cAMPS* sodium**	PKA	Neurological Disease Inflammation/Immunology
Rp-8-CPT-cAMPS sodium, a cAMP analog, is a potent and competitive antagonist of cAMP-induced activation of cAMP-dependent PKA I and II. Rp-8-CPT-cAMPS sodium preferentially selects site A of RI compares to site A of RII and site B of RII compares to site B of RI .

HY-137624

*Sp-cAMPS-AM*	PKA	Others
Sp-cAMPS-AM is an analog of cAMP. Sp-cAMPS-AM acts as the inducer of PKA activation and CREB phosphorylation, through entrance into the cell and release of its parent polar structure Sp-cAMPS .

Cat. No.	Product Name

HY-L165

Dopamine Receptor Compound Library

270 compounds

Dopamine receptor (DAR), widely distributed in the brain, plays a key role in regulating motor function, motivation, driving force and cognition. The role of DA is mediated by D1-type (D1, D5) and D2-type receptors (D2S, D2L, D3, D4), which are distributed in presynaptic, postsynaptic and extrasynaptic, projection neurons and interneurons. Each receptor has a different function. D1 and D5 receptors couple with G stimulation sites and activate Adenylyl cyclase. The activation of Adenylyl cyclase leads to the production of the second messenger cAMP, which leads to the production of protein kinase A (PKA), which leads to further transcription in the nucleus. D2 to D4 receptors are coupled to G inhibitory sites to inhibit adenylyl cyclase and activate potassium Ion channel. These receptors utilize phosphorylation cascades or direct membrane interactions to affect the functions of voltage-gated and neurotransmitter-gated channels, cytoplasmic enzymes, and transcription factors. Dopamine receptor plays an important role in daily life.

MCE designs a unique collection of 270 small molecules related to dopamine receptor. It is a good tool for screening drugs from nervous system disease.

Cat. No.	Product Name	Target	Research Area